Javier Naval

Campus San Francisco Sq
Zaragoza, AR, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab.

NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab.

Journal: Oncoimmunology
Published: September 25, 2025

Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat.

Alisertib and Barasertib Induce Cell Cycle Arrest and Mitochondria-Related Cell Death in Multiple Myeloma with Enhanced Efficacy Through Sequential Combination with BH3-Mimetics and Panobinostat.

Journal: Cancers
Published: May 30, 2025

Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.

Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.

Journal: Methods in cell biology
Published: October 11, 2024

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients.

Journal: Molecular oncology
Published: May 08, 2023

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak.

Study of the Bcl-2 Interactome by BiFC Reveals Differences in the Activation Mechanism of Bax and Bak.

Journal: Cells
Published: December 02, 2022

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.

Journal: Oncoimmunology
Published: November 07, 2022

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.

Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.

Journal: Cells
Published: December 21, 2021

Future prospects for mitosis-targeted antitumor therapies.

Future prospects for mitosis-targeted antitumor therapies.

Journal: Biochemical pharmacology
Published: May 06, 2021

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.

Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.

Journal: Oncoimmunology
Published: January 18, 2021

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Journal: Scientific reports
Published: July 24, 2020

Novel Forms of Immunomodulation for Cancer Therapy.

Novel Forms of Immunomodulation for Cancer Therapy.

Journal: Trends in cancer
Published: January 10, 2020

Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.

Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.

Journal: Frontiers in cell and developmental biology
Published: October 09, 2019
Showing 1-12 of 27

Last Updated: 09/26/2026